Mountain Valley MD (MVMD) AI Stock Analysis

• Market Cap: C$5.29M
• Dividend Yield: N/A
• Average Volume (3M): 205.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.43
• Revenue Growth: -46.59%
• EPS Growth: 8.26%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 352,354,950
• 10 Day Avg. Volume: 152,980
• 30 Day Avg. Volume: 205,595
• PEG Ratio: 0.14
• Price to Book (P/B): 3.44
• Price to Sales (P/S): 177.77
• P/FCF Ratio: -2.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$0.02 ▲(0.00% Upside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is held down primarily by weak financial performance—minimal/declining revenue, large losses, and persistent negative operating/free cash flow—despite low debt. Technicals provide a modest offset with price above key moving averages and a positive MACD, while valuation remains constrained by ongoing losses and no dividend support.

Positive Factors

Very Low Leverage

Effectively zero reported total debt materially reduces near-term default and interest burden risk. For a cash-burning developer, low leverage preserves optionality to raise capital or restructure without immediate debt servicing strain, supporting longer-term survival odds.

Improving Gross Profit

A return to positive gross profit indicates product-level economics can be positive once scale or cost controls improve. If sustained, this provides a structural pathway to improve operating margins as R&D and SG&A are better absorbed or optimized over time.

Lower Systematic Volatility

A low beta suggests the business is less sensitive to market swings, which can ease fundraising and strategic planning. Lower systematic volatility helps management execute longer horizon initiatives without the same market-driven funding pressure typical for higher-beta small-cap peers.

Negative Factors

Persistent Cash Burn

Consistent negative operating and free cash flow (~-C$3.9M in 2025) shows the company cannot self-fund operations. Structural reliance on external financing increases dilution and execution risk, constraining ability to invest in commercialization or R&D without new capital.

Eroded Equity Cushion

A steep decline in equity over several years materially reduces the balance-sheet buffer against losses. With limited retained capital, the company has less flexibility to absorb setbacks, increasing the probability of dilutive financings or constrained strategic options over the medium term.

Minimal, Volatile Revenue

An extremely small and volatile revenue base demonstrates limited commercial traction and weak revenue diversification. Such minimal sales cannot cover fixed costs, making margin recovery and sustainable profitability dependent on uncertain product wins or major cost reductions.

Mountain Valley MD Business Overview & Revenue Model

Company Description

Mountain Valley MD Holdings Inc., through its subsidiary, Mountain Valley MD Inc., operates as a health and wellness company. The company engages in the implementation and licensing of its technologies to pharmaceutical, vaccine, and nutraceutical third parties. It offers Quicksome oral drug formulation and delivery technologies; Quicksol solubility formulation technology; and dose sparing adjuvant. In addition, the company is developing IM032 for the treatment of male beagle dogs for comparing intramuscular and subcutaneous dosing. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.

How the Company Makes Money

Mountain Valley MD makes money through the commercialization of its proprietary health solutions. The company generates revenue from the sale of its pharmaceutical and nutraceutical products, leveraging its unique delivery systems and formulations. Additionally, MVMD may establish partnerships with other pharmaceutical firms to co-develop or license its technologies, which can provide significant revenue streams through licensing fees, royalties, and milestone payments. The company's focus on scalable and cost-effective solutions contributes to its earnings potential in both emerging and established markets.

Mountain Valley MD Financial Statement Overview

Summary

Financial profile remains very weak: revenue is minimal and volatile with a sharp year-over-year decline, the company is deeply loss-making (multi-million net loss), and operating/free cash flow are persistently negative (ongoing cash burn). The main offset is very low debt, but equity has eroded substantially, raising financing/dilution risk.

Income Statement

Revenue remains very small and volatile, with 2025 annual revenue down ~85% year over year (C$49k vs. C$60k). Profitability is materially weak: the company is deeply loss-making with negative operating profit and a net loss of ~C$7.5M in 2025, translating to extremely negative net margins. A positive point is that 2025 gross profit is positive (unlike 2024), but overall the income statement profile reflects an early-stage business with heavy operating spend relative to revenue and no clear earnings traction yet.

Balance Sheet

Leverage is a clear strength: reported total debt is effectively zero in 2024–2025 and very low historically, which reduces financial risk. However, the balance sheet has weakened meaningfully as equity declined from ~C$30.5M (2021) to ~C$2.5M (2025), consistent with ongoing losses eroding the capital base; returns on equity are strongly negative. Overall, low debt helps, but the shrinking equity cushion is a key concern.

Cash Flow

Cash generation is weak, with operating cash flow negative every year shown and worsening to about -C$3.9M in 2025. Free cash flow is also consistently negative (about -C$3.9M in 2025), indicating ongoing cash burn and continued reliance on external funding over time. While cash burn did not spike dramatically versus 2024, the persistent negative cash profile and lack of self-funding capacity are the central risks.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	31.00K	49.00K	60.00K	0.00	110.00K	0.00
Gross Profit	18.00K	49.00K	-346.00K	-446.00K	70.00K	-430.19K
EBITDA	-1.22M	-3.16M	-2.78M	-6.89M	-9.29M	-4.77M
Net Income	-5.96M	-7.47M	-7.67M	-7.44M	-9.71M	-8.14M
Balance Sheet
Total Assets	594.00K	2.74M	8.97M	16.77M	25.27M	31.61M
Cash, Cash Equivalents and Short-Term Investments	316.00K	1.72M	5.92M	9.71M	14.22M	19.51M
Total Debt	89.00K	0.00	0.00	6.00K	44.00K	84.00K
Total Liabilities	130.00K	209.00K	258.00K	591.00K	422.00K	1.11M
Stockholders Equity	464.00K	2.53M	8.71M	16.18M	24.85M	30.50M
Cash Flow
Free Cash Flow	-1.07M	-3.91M	-3.80M	-4.85M	-5.68M	-4.31M
Operating Cash Flow	-1.07M	-3.90M	-3.30M	-4.79M	-5.59M	-3.86M
Investing Cash Flow	187.00K	-290.00K	-503.00K	1.89M	-98.00K	-149.00K
Financing Cash Flow	89.00K	0.00	-6.00K	-1.60M	395.00K	21.78M

Mountain Valley MD Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MVMD, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.83 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MVMD.

Mountain Valley MD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MVMD	46 Neutral	C$5.29M	-1.56	-148.48%	―	-46.59%	8.26%
RVV	44 Neutral	C$8.37M	-4.56	-664.21%	―	―	-80.42%
PCLO	44 Neutral	C$8.46M	5.19	―	―	15.64%	58.47%
LOBE	42 Neutral	C$14.82M	-2.55	―	―	-100.00%	-8.70%
AYUR	40 Underperform	C$1.95M	-1.54	-271.33%	―	15.95%	-1.81%
CANB	40 Underperform	C$3.46M	-10.76	-11.42%	―	-5.87%	-239.53%

Mountain Valley MD Corporate Events

Mountain Valley MD Details Year-End Commercialization Gains Across Core Platforms

Mountain Valley MD issued a year-end update highlighting commercialization progress across its three main platforms, with management emphasizing disciplined execution in product development, field validation and commercial foundations as the business enters a new growth phase. In nutraceuticals, the company is scaling its Quicksome™ technology through an exclusive U.S.-based GMP manufacturing partner, supporting ongoing production for Circadian Wellness’s Quicksome™-based Eons sublingual products and advancing new licensing opportunities in areas such as menopause symptom relief, muscle recovery, anti-inflammation and joint health, while preparing a fenugreek glycosides testosterone product launch via a licensee in the first half of 2026 and positioning its “Mountains Of…” branded line for either direct or white-label distribution; in agriculture, MVMD continues to validate and commercialize its Agrarius technology across diverse crops and regions, reinforcing its potential role in sustainable farming and laying a data-driven foundation for longer-term adoption.

The most recent analyst rating on (TSE:MVMD) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on Mountain Valley MD stock, see the TSE:MVMD Stock Forecast page.